The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas.
 
Tianhong Li
Honoraria - Tempus
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); Nvigen (Inst); OncoImmune/OncoC4 (Inst); Pfizer (Inst); RasCal (Inst); Tempus (Inst)
 
Shuai Chen
No Relationships to Disclose
 
Weijie Ma
No Relationships to Disclose
 
Kit Wah Tam
No Relationships to Disclose
 
Rashmi Verma
No Relationships to Disclose
 
Chihong Zhou
No Relationships to Disclose
 
Laura Molnar
No Relationships to Disclose
 
Leslie A. Garcia
No Relationships to Disclose
 
Kris K. Johnston
No Relationships to Disclose
 
Kyra Toomey
No Relationships to Disclose
 
Dennis J. Montoya
No Relationships to Disclose
 
Jie Zeng
No Relationships to Disclose
 
Varun R. Viswanath
No Relationships to Disclose
 
Colleen A. Pineda
No Relationships to Disclose
 
Nancy L. Ogihara
No Relationships to Disclose
 
James A. Radosevich
Employment - LabyRx Immuno-Oncology
Stock and Other Ownership Interests - LabyRx Immuno-Oncology
Patents, Royalties, Other Intellectual Property - LabyRx Immuno-Oncology
 
Michael Babich
Employment - LabyRx Immuno-Oncology
Stock and Other Ownership Interests - LabyRx Immuno-Oncology
Patents, Royalties, Other Intellectual Property - LabyRx Immuno-Oncology